Advertisement


Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

COVID-19 and Cancer Care

Advertisement

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.



Related Videos

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 1

Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma?

Recorded April 21, 2020.

COVID-19
Global Cancer Care

Giorgio V. Scagliotti, MD, PhD, on the Ongoing Battle Against COVID-19: Update From Italy

Giorgio V. Scagliotti, MD, PhD, of the University of Turin, talks about the ways in which coronavirus reshaped Italian hospitals, mistakes made, and lessons learned. Filmed April 15, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 6

Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic?

Recorded April 21, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 2

During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission?

Recorded April 21, 2020.

COVID-19
Global Cancer Care

Eduardo L. Cazap, MD, PhD, on COVID-19: The View From South America

Eduardo L. Cazap, MD, PhD, of the Sociedad Latinoamericana y del Caribe de Oncología Médica, and an international editor on The ASCO Post Editorial Board, talks about the situation in Argentina treating patients with COVID-19, and the 10-country research effort led by the World Health Organization seeking to fast track research on the coronavirus. Filmed April 7, 2020.

Advertisement

Advertisement




Advertisement